Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on 31 March 2023 for its second-generation DSR product (DSR 2.0) for the treatment of congestive heart failure. Clearance of the IND will pave the way for the Company to initiate its randomized controlled Phase 1/2a MOJAVE study in the US, planned for Q2 2023.
The IND application includes data from the previously reported GLP animal1 and Phase 1 CHIHUAHUA2 studies supporting the safety and tolerability profile of Sequana Medical’s DSR 2.0 product, as well as the strong safety and efficacy data reported from RED DESERT and SAHARA proof-of-concept studies with its first-generation DSR product (DSR 1.0). Additionally, the application also contains manufacturing information of DSR 2.0 and an outline of the MOJAVE study design.
Oliver Gödje, Chief Medical Officer of Sequana Medical, commented: “Today’s announcement is an important milestone for our DSR program. There are an estimated 200,000 US heart failure patients suffering from diuretic-resistant congestion that requires repeated hospitalization at an estimated cost of $14bn a year, and therefore an urgent need for new therapies such as DSR to alleviate this burden and improve patients’ lives. We are very excited to build upon the exciting results from our RED DESERT and SAHARA studies and bring our second generation product, DSR 2.0 into the clinic in the US. We look forward to reporting data from the first US patients later this year.”
On track to start MOJAVE with DSR 2.0 in Q2 2023
The final study design of the randomized controlled Phase 1/2a MOJAVE study in the US will be communicated upon approval by the FDA and Ethics Committees. Following several initial discussions with the FDA, the intention is to enrol 30 diuretic-resistant chronic heart failure patients with persistent congestion. Of these, 20 randomized patients will receive DSR 2.0 administered via a peritoneal catheter on top of usual care for congestive heart failure for up to four weeks and ten randomized patients will receive intravenous loop diuretic treatment as part of maximized usual care for congestive heart failure alone. Following four weeks of treatment, there will be a three-month safety follow-up period. Prior to enrolment of these 30 patients, the intention is for three patients to be enrolled in a non-randomized safety cohort and to receive DSR 2.0 administered via a peritoneal catheter on top of congestive heart failure usual care for up to four weeks. Advancing to the enrolment of the 30 randomized patients is anticipated to be dependent upon DSMB3 approval following their review of the initial three patients.